ProCE Banner Activity

Frequently Asked Questions in HER2-Positive Metastatic Breast Cancer Care

Clinical Thought
Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with HER2-positive MBC.

Released: September 11, 2020

Expiration: September 10, 2021

No longer available for credit.

Share

Faculty

Cristina Saura

Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Cristina Saura, MD, PhD, has disclosed that she has received consulting fees or travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann-La Roche, Genomic Health, Merck, Novartis, Pfizer, Philips HealthWorks, Pierre Fabre, Puma, Sanofi, Seattle Genetics, and Synthon.